SS 27 - Advances in Multimodal Therapy for Glioblastoma: From Phase I to Phase III Trials

Presentations

• 12:30pm - 12:40pm ET

  Short-Course vs. Standard Radiotherapy with Concomitant and Maintenance Temozolomide in Patients Aged 18 to 70 years with Glioblastoma: An Open-Label, Randomized, Controlled, Phase 2, Non-Inferiority Trial

  Speaker: Samir Patel, MD - Associate Professor, University of Alberta, Edmonton
• 12:40pm - 12:50pm ET

  Targeting Recurrent Glioblastoma with Stereotactic Radiosurgery and Tumor Treating Fields Guided by 18F-FET-PET: Long-Term Results from a Prospective Phase 2 Trial (TTaRGeT)

  Speaker: Maciej Harat, MD, PhD - Franciszek Lukaszczyk Oncology Center, Bydgoszcz
• 12:50pm - 01:00pm ET

  Newly Adult Malignant Brainstem Glioma Treated with Anlotinib Plus Radiotherapy: A Multicenter, Phase II Study

  Speaker: Yuanyuan Chen, MD - Sun Yat-Sen University Cancer Center, Guang Dong Province
• 01:00pm - 01:10pm ET

  Replication-Competent Adenoviral Double-Suicide Therapy with fSRS in Progressive Glioblastoma (RAD-Gli): A Phase 1 Trial

  Speaker: Shyam Nyati, PhD - University of Michigan, Ann Arbor
• 01:10pm - 01:20pm ET

  Initial outcomes from a phase II study of multiparametric MR-guided high-dose response adaptive radiotherapy with concurrent temozolomide in patients with newly diagnosed glioblastoma

  Speaker: Michelle Kim, MD - University of Michigan, Ann Arbor
• 01:20pm - 01:30pm ET

  Intratumoral Heterogeneity of Mutational Drivers Associated with Radiation Response in Glioblastoma

  Speaker: Taylor Weiskittel, MD, PhD, MS - Mayo Clinic, Scottsdale
• 01:30pm - 01:40pm ET

  Discussant

  Speaker: Helen Shih, MD, MS, FASTRO, MPH, AM - Massachusetts General Hospital, Boston